Last reviewed · How we verify
NCT03184324
Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study)
Phase 2 trial testing DWP14012 in Erosive Gastroesophageal Reflux Disease in 211 participants. Completed in 18 April 2018.
18 April 2018
Quick facts
| Lead sponsor | Daewoong Pharmaceutical Co. LTD. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 211 |
| Start date | 28 August 2017 |
| Primary completion | 18 April 2018 |
| Estimated completion | 18 April 2018 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- DWP14012 — full drug profile →
- Esomeprazole (esomeprazole) — full drug profile →
- DWP14012 placebo
- Esomeprazole placebo
Conditions studied
- Erosive Gastroesophageal Reflux Disease — all drugs for Erosive Gastroesophageal Reflux Disease →
Sponsor
Daewoong Pharmaceutical Co. LTD. — full company profile →
Who can join
Adults 20 to 75, any sex, with Erosive Gastroesophageal Reflux Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine the efficacy and safety of DWP14012 compared to esomeprazole in the treatment of erosive gastroesophageal reflux disease classified as Los Angeles(LA) classification grades A to D.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03184324
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of DWP14012
Trials testing the same drug.
- NCT05812404 — Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects · Phase 1 · unknown
- NCT05574374 — Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects · Phase 1 · completed
- NCT05304845 — Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects · Phase 1 · completed
- NCT05813561 — The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis · Phase 3 · completed
- NCT04888819 — Treatment Effect According to Timing of Administration of DWP14012 40 mg · NA · unknown
Other Daewoong Pharmaceutical Co. LTD. trials
Trials by the same sponsor.
- NCT07515560 — Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study · not yet recruiting
- NCT07516977 — Noseguard for Prevention of Respiratory Infections in Real-World Use · NA · not yet recruiting
- NCT07539415 — A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Hea · Phase 1 · not yet recruiting
- NCT07267221 — Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers · Phase 1 · recruiting
- NCT07256600 — PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03184324 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Daewoong Pharmaceutical Co. LTD.
- Last refreshed: 3 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03184324.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing